Evidence map›Paper›PMID 30409823›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.

Cristina Puig-Saus, Giulia Parisi, Angel Garcia-Diaz, Paige E Krystofinski, Salemiz Sandoval, Ruixue Zhang, Ameya S Champhekar, James McCabe, Gardenia C Cheung-Lau, Nhat A Truong and 27 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Viral vector platforms within the gene therapy landscape.Signal transduction and targeted therapy · 2021
    Review
  4. Review
  5. Review
  6. Article
  7. Applications of molecular engineering in T-cell-based immunotherapies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 8 institutions in 1 country.

Cristina Puig-SausDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California. aribas@mednet.ucla.edu cpuigsaus@mednet.ucla.edu.
Giulia ParisiDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Angel Garcia-DiazDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Paige E KrystofinskiDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Salemiz SandovalDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Ruixue ZhangDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Ameya S ChamphekarDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
James McCabeDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Gardenia C Cheung-LauDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Nhat A TruongDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Agustin Vega-CrespoDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Marie Desiles S KomenanDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Jia PangDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Mignonette H MacabaliDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Justin D SacoDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Jeffrey L GoodwinDivision of Laboratory Animal Medicine (DLAM), Department of Medicine, DGSOM, UCLA, Los Angeles, California.
Brad BolonGEMpath, Inc., Longmont, Colorado.
Christopher S SeetDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Amelie Montel-HagenDepartment of Pathology and Laboratory Medicine, DGSOM, UCLA, Los Angeles, California.
Gay M CrooksJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California.
Roger P HollisDepartment of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California.
Beatriz Campo-FernandezDepartment of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California.
Daniela BischofDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indiana University Vector Production Facility, Indianapolis, Indiana.
Kenneth CornettaDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indiana University Vector Production Facility, Indianapolis, Indiana.
Eric H GschwengDepartment of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California.
Celia AdelsonEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, California.
Alexander NguyenDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Lili YangJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California.
Owen N WitteEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, California.
David BaltimoreDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, California.
Begonya Comin-AnduixJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California.
Donald B KohnDepartment of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California.ORCID 0000-0003-1840-6087
Xiaoyan WangStatistics Core, Department of Medicine, UCLA, Los Angeles, California.
Paula CabreraDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Paula J Kaplan-LefkoDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Beata Berent-MaozDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California.
Antoni RibasDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, California. aribas@mednet.ucla.edu cpuigsaus@mednet.ucla.edu.
University of California, Los Angeles · USIndiana University – Purdue University Indianapolis · USBroad Center · USCalifornia Animal Hospital · USCalifornia Institute of Technology · USChildren’s Institute · USNewPath Research · USUCLA Health · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CUMBERLAND, WILLIAM GLEN · 1991 to 2018
$39.9M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
National Gene Vector Biorepository and Coordinating Center at Indiana UniversityP40HL116242 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI CORNETTA, KENNETH · 2012 to 2017
$5.5M
NCI NIH HHS P01 CA168585NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NHLBI NIH HHS P40 HL116242NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

purposeTo improve persistence of adoptively transferred T-cell receptor (TCR)-engineered T cells and durable clinical responses, we designed a clinical trial to transplant genetically-modified hematopoietic stem cells (HSCs) together with adoptive cell transfer of T cells both engineered to express an NY-ESO-1 TCR. Here, we report the preclinical studies performed to enable an investigational new drug (IND) application. EXPERIMENTAL

designHSCs transduced with a lentiviral vector expressing NY-ESO-1 TCR and the PET reporter/suicide gene HSV1-sr39TK and T cells transduced with a retroviral vector expressing NY-ESO-1 TCR were coadministered to myelodepleted HLA-A2/K

resultsTCR genetically modified and

conclusionsCoadministration of HSCs and T cells expressing an NY-ESO-1 TCR is safe in preclinical models. The results presented in this article led to the FDA approval of IND 17471.

Indexed as

AnimalsAntigens, NeoplasmCells, CulturedClinical Trials as TopicDrugs, InvestigationalGenetic TherapyHematopoietic Stem CellsHLA-A2 AntigenHumansImmunotherapy, AdoptiveMembrane ProteinsMice, Inbred C57BLMice, TransgenicNeoplasmsReceptors, Antigen, T-CellT-LymphocytesAntigens, NeoplasmCTAG1B protein, humanDrugs, InvestigationalHLA-A2 AntigenMembrane ProteinsReceptors, Antigen, T-Cell

Identifiers

PMID30409823
PMCPMC6359988
OpenAlexW2899818309

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.